Should Bladder Biopsies be Performed Routinely after Bacillus Calmette-Guérin Treatment for High-Risk Superficial Transitional Cell Cancer of the Bladder?

European Urology

Volumn 50, Issue 3, 2006, Pages 516-520

  Guy, Laurent ^a   Savareux, Laurent ^a,b   Molinié, Vincent ^b   Botto, Henry ^b   Boiteux, Jean Paul ^a   Lebret, Thierry ^b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b FOCH HOSPITAL   (France)

Author keywords

BCG vaccine; Biopsy; Bladder neoplasms

Indexed keywords

BCG VACCINE;

ANALYTICAL PARAMETERS; ARTICLE; BCG VACCINATION; BLADDER BIOPSY; BLADDER CANCER; CANCER GROWTH; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; HIGH RISK PATIENT; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR BIOPSY; URINE CYTOLOGY;

BCG VACCINE; BIOPSY; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 33746929941     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.03.022     Document Type: Article

References (26)

1. Malkowicz S.B. Management of superficial bladder cancer. In: Walsh P.C., Retik A.B., Vaughan Jr. E.D., and Wein A.J. (Eds). Campbell's urology. 8th ed. vol. 4 (2002), WB Saunders Co, Philadelphia 2785-2802 sect X, chap 77
2. Lamm D.L. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19 (1992) 573-580
3. Shelley M.D., Kynaston H., Court J., et al. A systemic review of intravesical Bacillus Calmette-Guérin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int 88 (2001) 209-216
4. Whelan P. Treatment of superficial bladder cancer: a discussion on intravesical immunotherapy and intravesical chemotherapy. Eur Urol Suppl 3 3 (2004) 70-72
5. Lebret T., Gaudez F., Hervé J.M., Barré P., Lugagne P.M., and Botto H. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 34 (1998) 67-72
6. Lebret T., Bohin D., Kassardjian Z., et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol 163 (2000) 63-67
7. Herr H.W., Wartinger D.D., Fair W.R., and Oettgen H.F. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol 147 (1992) 1020-1023
8. Dalbagni G., Rechtschaffen T., and Herr W.H. Is transurethral biopsy of the bladder necessary after 3 months to evaluate response to Bacillus Calmette-Guerin therapy?. J Urol 162 (1999) 708-709
9. Skemp N.M., and Fernandes E.T. Routine bladder biopsy after Bacille Calmette-Guerin treatment: is it necessary?. Urology 59 (2002) 224-226
10. Highshaw R.A., Tanaka S.T., Evans C.P., and Devere White W.R. Is bladder biopsy necessary at three or six months post BCG therapy?. Urol Oncol 21 (2003) 207-209
11. Sobin L.H., and Wittekind C. TNM classification of malignant tumours. 5th ed. (1997), Wiley-Liss Publications, New York p. 187-90
12. Epstein J.I., Amin M.B., Reuter V.R., and Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22 (1998) 1435-1448
13. Oosterlink W., Lobel B., Jakse G., Malmström P.-U., Stöckle M., and Sternberg C. EAU Guidelines. Guidelines on bladder cancer (2001), European Association of Urology
14. Smith JA, Labasky RF, Montie JE, Rowland RG, Cockett ATK, Fracchia JA. AUA Guidelines. Report on the management of non-muscle-invasive bladder cancer (Stages Ta, T1 and Tis). 1999.
15. Herr H.W., Laudone V.P., Badalament R.A., et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6 (1988) 1450-1455
16. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
17. Witjes J.A. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45 (2004) 142-146
18. Lamm D.L., Crawford E.D., Blumenstein B., et al. Maintenance BCG immunotherapy of superficial bladder cancer. A randomized prospective Southwest Oncology Group study. J Urol 147 (1992) 247A (abstract no. 242)
19. Lamm D.L., Blumenstein B., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
20. Lamm D.L. Preventing progression and improving survival with BCG maintenance. Eur Urol 37 (2000) 9-15
21. Shenoy U.A., Colby T.V., and Schumann G.B. Reliability of cytodiagnosis in urothelial neoplasms. Cancer 56 (1985) 2041-2045
22. Bastacky S., Ibrahim S., Wilczynski S.P., and Murphy W.M. The accuracy of urinary cytology in daily practice. Cancer 87 (1999) 118-128
23. Wiener H.G., Vooijs G.P., and van't Hof-Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 37 (1993) 163-169
24. Ro J.Y., Staerkel G.A., and Ayala A.G. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 19 (1992) 435-453
25. Molinié V., Longchampt E., Ouazana D., and Lebret T. Bladder tumors and molecular markers. Current status and perspectives. Ann Pathol 23 (2003) 306-331
26. Oosterlinck W., Bono A.V., Mack D., et al. Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. Eur Urol 40 (2001) 515-517